FEBRUARY 28, 2022
Panthera Dental’s commitment to innovation in OSA therapy has led to an expansion of its product range to include a pediatric oral appliance. This new option enables practitioners to close a treatment gap. Pediatric OSA is known to be present in up to 5% of children. If not recognized and treated OSA can have lifelong consequences for health, academic performance and overall well-being. Previously named SomNyx, the appliance will be rebranded as D-SAD|Myo within Panthera Dental’s digital sleep appliance range.
It is a clinically tested treatment, combining aspects of MFT with an oral mandibular advancement appliance. MFT alone has shown some promise in the treatment of OSA, however it typically requires parental involvement which is difficult to sustain over time. The D-SAD|Myo reduces that need. Rather than the required parental intervention, the D-SAD|Myo provides the means for the child to independently perform the tongue exercises with the device in place, improving adherence to therapy.
The appliance incorporates two unique elements, the patient-tailored mandibular appliance and a rolling-ball mechanism. The ball promotes forward tongue movement which stimulates the genioglossus muscle responsible for tongue protrusion and tone, while preventing its posterior displacement and upper airway closure. Clinical trial data from several international studies have demonstrated significantly improved breathing during sleep in children with OSA. There was a concomitant increase in nasopharyngeal airway space with improved nasal breathing, and an increase in the mandibular counter clockwise growth. While the impact on growth is only possible in children, adults may benefit from this appliance’s myofunctional training as well.
At the upcoming World Sleep Congress in Rome, in a symposium dedicated to orthodontic treatments of sleep disorders for children, Dr. Hervy will present the latest results from clinical studies evaluating this novel appliance therapy.
This treatment is supported by clinical studies conducted under the direction of French physician and prolific sleep medicine researcher Professor Christian Guilleminault, former director of the sleep centre of the University of Stanford and author of over 700 publications including the key clinical study evaluating this new therapy.
The D-SAD|Myo is planned for launch in the E.U. and U.S. in 2023, pending regulatory authorizations.
[…]
Continue reading the press release here:
